2.780USD+3.81%Mkt Cap: 353.91M USDP/E: —Last update: 2026-06-01
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops N…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap353.91M USD
Enterprise Value281.20M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.00M USD
Revenue/Share—
Last Price2.780 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees127
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.70
PEG—
EV/EBITDA-4.50
EV/Revenue—
P/S—
P/B2.41
EPS (TTM)-0.46
EPS (Forward)-0.74
52W Range
0.620059% of range4.310
52W High4.310 USD
52W Low0.6200 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-37.59%
ROA-30.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-50.70M USD
CapEx (TTM)1.28M USD
FCF Margin—
FCF Yield-8.16%
Net Debt-67.00M USD
Net Debt/EBITDA1.07
Balance Sheet
Debt/Equity0.19
Current Ratio11.85
Quick Ratio11.49
Book Value/Sh1.136 USD
Cash/Share0.7540 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.000 USD
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.127.08M
Float47.22M
Insiders33.21%
Institutions47.44%
Short Interest
Short Ratio2.4d
Short % Float1.32%
Short % Out.0.65%
Shares Short825.03K
Short (prev mo.)638.94K
Technical
SMA 502.942 (-5.5%)
SMA 2001.962 (+41.7%)
Beta0.75
S&P 52W Chg27.94%
Avg Vol (30d)361.15K
Avg Vol (10d)438.28K
Technical Indicators
RSI (14)49.9
MACD-0.0806
MACD Signal-0.0939
MACD Hist.+0.0133
BB Upper3.104 USD
BB Middle2.674 USD
BB Lower2.244 USD
BB Width32.13%
ATR (14)0.2231 USD
Vol Ratio (20d)0.97x